All News

While it is often difficult to defend a case involving the removal of an organ for cancer that is then determined to be cancer free, the added claim of lack of informed consent for the procedure does not aid the defense in these lawsuits.

A novel imaging technique may prove more effective than current magnetic resonance imaging approaches for localizing prostate tumors, researchers say.

A combination vaccine and androgen ablation therapy is showing promise in some patients with prostate cancer.

Get comprehensive coverage-including web-exclusive content and videos-on prostate cancer treatment and current controversies.

An advanced prostate cancer treatment protocol incorporating testosterone shows promise for treating the disease and reversing resistance to androgen deprivation therapy.

The FDA has approved ceftolozane/tazobactam (Zerbaxa) for the treatment of adults with complicated urinary tract infections.

Just over a year ago, the Office of Inspector General of the Department of Health and Human Services issued a report declaring that Medicare payments for vacuum erection systems were “grossly excessive” and recommended steps to remedy the situation.

Read and learn from Henry Rosevear, MD who experienced first hand how falls in the elderly are common and serious.

In this video, Edward Karpman, MD, shows how he performs microsurgical two-layer vasovasostomy to reconstruct the vas deferens after vasectomy.

Urologists at the University of Southern California’s Institute of Urology in Los Angeles are taking robotic kidney surgery to a new level. Inderbir S. Gill, MD, MCh, executive director of the USC Institute of Urology, has pioneered the use of the robot in patients with complex (level III) inferior vena cava thrombi.

Advances in the diagnosis and treatment of prostate cancer are among the great medical accomplishments of the latter part of the 20th century and beginning of the 21st. Five-year survival rates for newly diagnosed loco-regional cancer advanced from 68% in 1975-’77 to 83% in 1987-’89 to nearly 100% in 2003-’09, according to the American Cancer Society. This victory, however impressive, is incomplete.

The addition of radiation treatment to hormone therapy reduces mortality in older men with locally advanced prostate cancer compared with hormone therapy alone, according to a recently published study in the Journal of Clinical Oncology.

A genomic test for prostate cancer was able to predict rapid metastatic disease in node-negative, high-risk men managed by radical prostatectomy without adjuvant therapy in a recently published study.

New products and services from Samsung Electronics America, Syneron Medical, American Medical Systems, New Star, Buffalo Filter, Cook Medical, Endo International, Trimel BioPharma Metamark, and the National Comprehensive Cancer Network.

The rate of prostate biopsy declined steadily and significantly over a contemporary 10-year period, results of a retrospective longitudinal review of data from the Veterans Health Administration show.

Our January 2015 installment in the ongoing "New Frontiers in Prostate Cancer" series focuses on the challenges presented by high-risk disease. Here are some video resources on high-risk prostate cancer.

Our January 2015 installment in the ongoing "New Frontiers in Prostate Cancer" series focuses on the challenges presented by high-risk disease. Here are some recommended articles about the diagnosis and treatment of high-risk prostate cancer.

In this interview, Arie Belldegrun, MD, discusses the benefits of cancer immunotherapy, the importance of a multidisciplinary treatment approach, and what the future holds for this treatment.

The 2015 omnibus spending bill canceled a $10 million appropriation for the Independent Payment Advisory Board (IPAB). Congress also approved a bill that cuts Medicare funding for vacuum erection systems. Rationing care, whether undertaken by the IPAB or Congress, must be opposed when it arbitrarily selects services based on public perception and not medical necessity, writes Ross E. Weber of the AACU.

Drugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.

Certain private payers are denying codes for prostate and renal biopsy, and strong documentation will be required to ensure you get paid for your services.

Urology Times continues its "Year in Review" series with a look at the most-read men's health articles of 2014.

In this installment of our "Year in Review" series, we look at 2014's malpractice headlines, with commentary from Urology Times Editorial Council member John J. Mulcahy, MD, PhD.

This slideshow offers insight into the type and size of U.S. urologists’ practices, as well as their gender, based on results of the Urology Times 2014 State of the Specialty survey.

Urology Times looks back on the top health policy and practice management stories of 2014, including coverage of the Affordable Care Act and changes in reimbursement.

Ureteroscopy is being increasingly used for surgical management of nephrolithiasis in pediatric patients, and that trend appears to be associated with cost benefits, a recent study indicates.

Flexible ureteroscopy is a safe and highly effective approach for treating proximal ureteral stones measuring